Company
TCF +7.69%TheracryF PLC
Market Cap: £4.2 Million
GBP as of Aug 2, 2026 | US$5.6 Million
$TCF +7.69% $TCF United Kingdom Healthcare Biotechnology UK Healthcare UK BiotechnologyCompany Description
TheracryF PLC is an innovative player in the pharmaceutical and biotechnology industry. This company specializes in the development and commercialization of cutting-edge therapeutic solutions. Focused on addressing unmet medical needs, TheracryF PLC invests heavily in research and development to bring new drugs and treatments to market. The company's portfolio includes a range of products targeting various critical health conditions, enhancing patient care and improving life quality. By partnering with healthcare providers, research institutions, and regulatory bodies, TheracryF PLC ensures the safe and efficient deployment of its pharmaceutical products. As a pivotal entity in the biotech sector, TheracryF PLC contributes significantly to healthcare advancements, fostering medical innovation and supporting public health initiatives worldwide. Its strategic initiatives and rigorous approach to product development underscore its relevance and impact within the global financial markets, making it a key entity to watch in the ever-evolving landscape of healthcare solutions.
TheracryF PLC Market Capitalization Over Time
View HistoryEvolution of TheracryF PLC market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
TheracryF PLC is an innovative player in the pharmaceutical and biotechnology industry. This company specializes in the development and commercialization of cutting-edge therapeutic solutions. Focused on addressing unmet medical needs, TheracryF PLC invests heavily in research and development to bring new drugs and treatments to market. The company's portfolio includes a range of products targeting various critical health conditions, enhancing patient care and improving life quality. By partnering with healthcare providers, research institutions, and regulatory bodies, TheracryF PLC ensures the safe and efficient deployment of its pharmaceutical products. As a pivotal entity in the biotech sector, TheracryF PLC contributes significantly to healthcare advancements, fostering medical innovation and supporting public health initiatives worldwide. Its strategic initiatives and rigorous approach to product development underscore its relevance and impact within the global financial markets, making it a key entity to watch in the ever-evolving landscape of healthcare solutions.
Financials
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | £0 |
| EBITDA | £-2,207,000 |
| Gross Profit TTM | £-2,233,000 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |